The first PARP inhibitor approved as a monotherapy for the treatment of advanced ovarian cancer, olaparib, is now available for the treatment of BRCA-mutated ovarian, fallopian tube, breast, peritoneal, prostate, and metastatic pancreatic cancers. Here, PARP1 is linked to ovarian carcinoma.